Yunnan Peak Innovation Appraisal Model Marketers Debriefing Ratio Performance
Release time:
2020-08-14
Yunnan Peak Innovation Appraisal Mode
Marketers Debriefing Ratio Performance
News Through debriefing one by one, highlighting achievements and finding shortcomings, and choosing from the appraisal level, 2017 Yunnan Peak Cement Company has a new appraisal mode for outstanding salesmen.
12 24 , Yunnan peak organized the market, quality inspection, finance, production and other relevant departments to hold the sales analysis summary meeting of 2017 , summarizing the market sales work of 2017 , and selecting the outstanding employees and salesmen of the department. At the
meeting, the marketing department made a comprehensive summary of the sales work throughout the year, expressed its own views on the existing problems, analyzed the causes and solutions of the problems, and made an analysis and target confirmation of the market in 2018 . In 2017 , Yunnan Jianfeng achieved a new breakthrough in both volume and price. Cement sales achieved the annual target. Jianfeng Cement became a high-end brand and a synonym for good cement in southwest Yunnan, and was also the brand with the highest terminal sales price of cement in southwest Yunnan. Do a good job in market maintenance in rainy and off-season, and the sales volume of cement for large-scale projects has been greatly improved. Internal control management has been more refined, further reduced, further reduced, with no new receivables, at the same time, the contract, guarantee, customer credit, credit management, etc. to achieve no loopholes.
Compared with the past, this meeting has specially added the part of salesmen's debriefing. The salesmen in each district summarized themselves at the meeting and reported their work this year, so that the salesmen can more clearly realize their own shortcomings and gaps. Through the form of self-evaluation and self-selection, Yunnan Peak selected the outstanding marketer of the year.
Yunnan Jianfeng General Manager Zhou Jiping and Deputy General Manager Fang Xuhua affirmed the work of the marketing department this year, pointed out the shortcomings and areas that need improvement in the work of the marketing department, and put forward requirements for the sales work of the marketing department in 2018 . (hu chuanli)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31